As serine/threonine kinase, the cyclin dependent kinase 2 (CDK2) is a promising target for various diseases such as cerebral hypoxia, cancer, and neurodegenerative diseases. Here we reported the structure-based synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as CDK2 inhibitors, which exhibited potent CDK2 inhibitory activities, as well as anticancer activities in low concentration against two human cancer cell lines (MCF-7 and HCT116). In particular, compounds 11a and 11f (IC₅₀ values of 0.11 and 0.09 μM for CDK2, respectively) have demonstrated significantly inhibitory potency against CDK2 and have showed great inhibitory activities against MCF-7 and HCT116 cell lines.

作为丝氨酸/苏氨酸激酶，细胞周期蛋白依赖性激酶2（CDK2）是各种疾病（如脑缺氧，癌症和神经退行性疾病）的有希望的靶标。在这里我们报道了作为CDK2抑制剂的新型5,6-二氢嘧啶基[4,5- f ]喹唑啉衍生物的结构化合成和生物学评估，该化合物表现出有效的CDK2抑制活性，以及​​低浓度时对两种人类癌症的抗癌活性。细胞系（MCF-7和HCT116）。尤其是，化合物11a和11f（对于CDK2的IC ₅₀值分别为0.11和0.09μM）已显示出对CDK2的显着抑制作用，并且对MCF-7和HCT116细胞系显示出极大的抑制活性。